Ascendis Pharma A/S (NASDAQ:ASND) Sets New 52-Week High - Here's What Happened

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report)'s stock price reached a new 52-week high on Monday . The company traded as high as $168.74 and last traded at $167.04, with a volume of 130347 shares. The stock had previously closed at $152.98.

Analyst Ratings Changes

ASND has been the subject of several analyst reports. Evercore ISI raised their price objective on Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a report on Tuesday, February 18th. UBS Group began coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a "buy" rating and a $196.00 price target for the company. Morgan Stanley set a $180.00 price objective on Ascendis Pharma A/S in a research note on Tuesday, February 18th. JPMorgan Chase & Co. increased their price objective on Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an "overweight" rating in a report on Tuesday. Finally, Cantor Fitzgerald boosted their target price on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a report on Tuesday, February 25th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $204.64.

Ascendis Pharma A/S Trading Up 1.7 %

The firm has a market capitalization of $10.07 billion, a P/E ratio of -23.38 and a beta of 0.62. The stock's 50-day simple moving average is $140.63 and its 200-day simple moving average is $135.50.

Remove Ads

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.32) by $0.64. On average, equities research analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Institutional Trading of Ascendis Pharma A/S

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Ascendis Pharma A/S during the fourth quarter worth about $28,000. Wilmington Savings Fund Society FSB bought a new stake in Ascendis Pharma A/S during the third quarter valued at approximately $30,000. Jones Financial Companies Lllp grew its stake in Ascendis Pharma A/S by 394.0% in the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after buying an additional 197 shares in the last quarter. Blue Trust Inc. increased its holdings in shares of Ascendis Pharma A/S by 415.2% in the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock worth $56,000 after buying an additional 328 shares during the last quarter. Finally, Groupama Asset Managment purchased a new stake in shares of Ascendis Pharma A/S during the 3rd quarter valued at $60,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.